Lindsay J Caverly
Overview
Explore the profile of Lindsay J Caverly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carmody L, Caverly L, Kalikin L, Thornton C, Simon R, VanDevanter D, et al.
J Cyst Fibros
. 2024 Dec;
PMID: 39627109
Treatment-associated differences in Pseudomonas aeruginosa (Pa) density in sputum have been used as a response biomarker in clinical trials of cystic fibrosis (CF) therapies. Although most studies have included placebo-treated...
2.
Vazquez Deida A, Spicer K, McNamara K, Arduino M, Gable P, Halpin A, et al.
MMWR Morb Mortal Wkly Rep
. 2024 Oct;
73(39):883-887.
PMID: 39361547
Ice machines can harbor water-related organisms, and the use of ice or tap water for clinical care activities has been associated with infections in health care settings. During 2021-2022, a...
3.
Magaret A, Graham E, Caverly L, Cromwell E, Paynter A, Rosenfeld M, et al.
J Cyst Fibros
. 2024 Aug;
23(5):943-946.
PMID: 39147620
Clinical trials often demonstrate treatment efficacy through change in forced expiratory volume in one second (FEV), comparing single FEV measurements from post- versus pre-treatment timepoints. Day-to-day variation in measured FEV...
4.
Dowdell K, Potgieter S, Olsen K, Lee S, Vedrin M, Caverly L, et al.
Appl Environ Microbiol
. 2024 Aug;
90(9):e0060924.
PMID: 39109876
Nontuberculous mycobacteria (NTM) in drinking water are a significant public health concern. However, an incomplete understanding of the factors that influence the occurrence of NTM in drinking water limits our...
5.
Widder S, Carmody L, Opron K, Kalikin L, Caverly L, LiPuma J
Nat Commun
. 2024 Jun;
15(1):4889.
PMID: 38849369
Polymicrobial infection of the airways is a hallmark of obstructive lung diseases such as cystic fibrosis (CF), non-CF bronchiectasis, and chronic obstructive pulmonary disease. Pulmonary exacerbations (PEx) in these conditions...
6.
Breen P, Zimbric M, Caverly L
PLoS One
. 2024 May;
19(5):e0303516.
PMID: 38728330
Increasingly prevalent, nontuberculous mycobacteria (NTM) infections affect approximately 20% of people with cystic fibrosis (CF). Previous studies of CF sputum identified lower levels of the host metabolite itaconate in those...
7.
8.
9.
Thornton C, Caverly L, Kalikin L, Carmody L, McClellan S, LeBar W, et al.
Ann Am Thorac Soc
. 2023 Nov;
21(4):595-603.
PMID: 37963297
Rates of viral respiratory infection (VRI) are similar in people with cystic fibrosis (CF) and the general population; however, the associations between VRI and CF pulmonary exacerbations (PEx) require further...
10.
Widder S, Opron K, Carmody L, Kalikin L, Caverly L, LiPuma J
bioRxiv
. 2023 Aug;
PMID: 37546739
Polymicrobial infection of the airways is a hallmark of obstructive lung diseases such as cystic fibrosis (CF), non-CF bronchiectasis, and chronic obstructive pulmonary disease (COPD). Intermittent pulmonary exacerbations (PEx) in...